BACKGROUND/AIMS: Carbonic anhydrase isoenzyme IX (MN/CA IX) is a transmembrane protein with a suggested function in maintaining the acid-base balance and intercellular communication. Previous studies have demonstrated that MN/CA IX is expressed in the basolateral plasma membrane of normal biliary epithelial cells, but not in hepatocytes. This study was designed to examine the expression of MN/CA IX in hepatobiliary neoplasms and to elucidate its value as a marker for biliary differentiation. METHODS: Fifty-seven hepatobiliary lesions were immunostained for MN/CA IX using biotin-streptavidin complex method. Twenty samples containing normal biliary epithelium and five containing normal liver tissue were used as controls. RESULTS: In the biliary epithelial tumours, immunostaining for MN/CA IX was mainly localized at the basolateral surface of the epithelial cells, like in normal mucosa. All non-invasive dysplastic lesions and 57% of invasive lesions of gall-bladder expressed MN/CA IX. In liver, 78% of cholangiocellular malignant lesions showed a positive reaction for MN/CA IX, whereas only 33% of hepatocellular carcinomas showed a weak immunoreaction. CONCLUSIONS: Our results suggest that abnormal expression of MN/CA IX may be linked to malignant transformation of hepatobiliary cells. In addition, it seems to be a promising marker for biliary differentiation in hepatobiliary neoplasms.
BACKGROUND/AIMS: Carbonic anhydrase isoenzyme IX (MN/CA IX) is a transmembrane protein with a suggested function in maintaining the acid-base balance and intercellular communication. Previous studies have demonstrated that MN/CA IX is expressed in the basolateral plasma membrane of normal biliary epithelial cells, but not in hepatocytes. This study was designed to examine the expression of MN/CA IX in hepatobiliary neoplasms and to elucidate its value as a marker for biliary differentiation. METHODS: Fifty-seven hepatobiliary lesions were immunostained for MN/CA IX using biotin-streptavidin complex method. Twenty samples containing normal biliary epithelium and five containing normal liver tissue were used as controls. RESULTS: In the biliary epithelial tumours, immunostaining for MN/CA IX was mainly localized at the basolateral surface of the epithelial cells, like in normal mucosa. All non-invasive dysplastic lesions and 57% of invasive lesions of gall-bladder expressed MN/CA IX. In liver, 78% of cholangiocellular malignant lesions showed a positive reaction for MN/CA IX, whereas only 33% of hepatocellular carcinomas showed a weak immunoreaction. CONCLUSIONS: Our results suggest that abnormal expression of MN/CA IX may be linked to malignant transformation of hepatobiliary cells. In addition, it seems to be a promising marker for biliary differentiation in hepatobiliary neoplasms.
Authors: Mari Leppilampi; Tuomo J Karttunen; Jyrki Kivelä; Marta Ortova Gut; Silvia Pastoreková; Jaromir Pastorek; Seppo Parkkila Journal: Transgenic Res Date: 2005-10 Impact factor: 2.788
Authors: Sean Carlin; Nahida Khan; Thomas Ku; Valerie A Longo; Steve M Larson; Peter M Smith-Jones Journal: PLoS One Date: 2010-05-27 Impact factor: 3.240
Authors: Mari Leppilampi; Juha Saarnio; Tuomo J Karttunen; Jyrki Kivelä; Silvia Pastoreková; Jaromir Pastorek; Abdul Waheed; William S Sly; Seppo Parkkila Journal: World J Gastroenterol Date: 2003-07 Impact factor: 5.742
Authors: Ann Driessen; Willy Landuyt; Sylvia Pastorekova; Johnny Moons; Laurence Goethals; Karin Haustermans; Philippe Nafteux; Freddy Penninckx; Karel Geboes; Toni Lerut; Nadine Ectors Journal: Ann Surg Date: 2006-03 Impact factor: 12.969
Authors: Heini Kallio; Silvia Pastorekova; Jaromir Pastorek; Abdul Waheed; William S Sly; Susanna Mannisto; Markku Heikinheimo; Seppo Parkkila Journal: BMC Dev Biol Date: 2006-05-23 Impact factor: 1.978
Authors: Merja Vakkala; Jouko J Laurila; Juha Saarnio; Vesa Koivukangas; Hannu Syrjälä; Tuomo Karttunen; Ylermi Soini; Tero I Ala-Kokko Journal: Crit Care Date: 2007 Impact factor: 9.097